Full Press Release Details
Cellectar Biosciences
Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform
Nature Reviews Clinical
Oncology Online Publication and Oral Presentation at Academic Surgical Congress Further Demonstrate the Potential of
Madison, Wisc, (January
31, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused,
clinical stage biotechnology company, today announces the advance online publication of an article
in Nature Reviews Clinical Oncology. In addition, the company anticipates an oral presentation on its drug delivery platform
at the Academic Surgical Congress on February 8, 2017, at the Encore Hotel, Las Vegas. Each publication increases our understanding
regarding the unique tumor targeting ability of the company's phospholipid drug conjugates (PDCs) with fluorescent payloads.
The Nature Reviews Clinical Oncology
article, titled "Beyond the Margins: Real-Time Detection of Cancer Using Targeted Fluorophores," evaluates the current
use of fluorescent molecules in cancer diagnostics and fluorescence-guided surgical resection of tumors. It focuses on the need
for the use of targeted delivery of fluorescent molecules to malignant tissue. Specifically, it highlights near-infrared fluorescent
molecules such as CLR 1502 in order to provide clear margins between healthy tissue and tumor tissue, thereby potentially improving
patient outcomes post-surgical resection.
During the Academic Surgical Conference, John
S. Kuo, M.D., Ph.D., associate professor, Neurosurgery, University of Wisconsin-Madison School of Medicine and Public Health, will
discuss abstract #ASC20171140 titled "Effects of Intralipid on Serum Partitioning of Cancer-targeting Alkylphosphocholine
Analogs." The presentation will take place during the "Basic Science: Oncology 1 Quickshot" session at 2:30 PM
PT in the Encore Hotel's Beethoven Room 1. Dr. Kou's presentation will demonstrate how changes in plasma lipid concentrations
can alter the protein binding of PDC molecules and potentially result in more rapid and increased delivery of PDCs like CLR 1501
and CLR 1502 to malignant tissue.
"The peer reviewed data in these two reports contribute
to our understanding of the PDC delivery platform; particularly, the potential clinical utility of our imaging assets," said
Jim Caruso, president and CEO of Cellectar Biosciences. "These two prestigious venues provide additional validation of the
unique potential and varied utility of our platform."
About Phospholipid Drug Conjugates (PDCs)
Cellectar's product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized
phospholipid ether-drug conjugates (PDCs). The company deliberately designed its phospholipid ether (PLE) carrier platform to be
coupled with a variety of payloads to facilitate both therapeutic and diagnostic applications. The basis for selective tumor targeting
of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells. Cancer
cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that
contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules.
PDCs have been tested in more than 80 different xenograft models of cancer.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse
oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma. In addition, the
company plans to initiate a Phase II clinical study to assess efficacy in a range of B-cell malignancies in the first quarter of
2017. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical
stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D
efforts. For more information please visit www.cellectar.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause
actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business
is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended
December 31, 2015. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to
update any such forward-looking statements.